High risk for suicide is associated with T-cell abnormalities in patients with major depressive disorder

2019 ◽  
Vol 29 ◽  
pp. S59 ◽  
Author(s):  
C. Schiweck ◽  
H. Drexhage ◽  
S. Claes ◽  
E. Vrieze
2000 ◽  
Vol 57 (9) ◽  
pp. 867 ◽  
Author(s):  
Boris Birmaher ◽  
Ronald E. Dahl ◽  
Douglas E. Williamson ◽  
James M. Perel ◽  
David A. Brent ◽  
...  

2016 ◽  
Vol 46 (11) ◽  
pp. 2351-2361 ◽  
Author(s):  
T. Nickson ◽  
S. W. Y. Chan ◽  
M. Papmeyer ◽  
L. Romaniuk ◽  
A. Macdonald ◽  
...  

BackgroundPrevious neuroimaging studies indicate abnormalities in cortico-limbic circuitry in mood disorder. Here we employ prospective longitudinal voxel-based morphometry to examine the trajectory of these abnormalities during early stages of illness development.MethodUnaffected individuals (16–25 years) at high and low familial risk of mood disorder underwent structural brain imaging on two occasions 2 years apart. Further clinical assessment was conducted 2 years after the second scan (time 3). Clinical outcome data at time 3 was used to categorize individuals: (i) healthy controls (‘low risk’, n = 48); (ii) high-risk individuals who remained well (HR well, n = 53); and (iii) high-risk individuals who developed a major depressive disorder (HR MDD, n = 30). Groups were compared using longitudinal voxel-based morphometry. We also examined whether progress to illness was associated with changes in other potential risk markers (personality traits, symptoms scores and baseline measures of childhood trauma), and whether any changes in brain structure could be indexed using these measures.ResultsSignificant decreases in right amygdala grey matter were found in HR MDD v. controls (p = 0.001) and v. HR well (p = 0.005). This structural change was not related to measures of childhood trauma, symptom severity or measures of sub-diagnostic anxiety, neuroticism or extraversion, although cross-sectionally these measures significantly differentiated the groups at baseline.ConclusionsThese longitudinal findings implicate structural amygdala changes in the neurobiology of mood disorder. They also provide a potential biomarker for risk stratification capturing additional information beyond clinically ascertained measures.


Author(s):  
BORIS BIRMAHER ◽  
JEFFREY A. BRIDGE ◽  
DOUGLAS E. WILLIAMSON ◽  
DAVID A. BRENT ◽  
RONALD E. DAHL ◽  
...  

2020 ◽  
Author(s):  
Richard Neugebauer ◽  
Priya Wickramaratne ◽  
Connie Svob ◽  
Clayton McClintock ◽  
Marc J. Gameroff ◽  
...  

Background. In most studies, religiosity and spirituality (R/S) are positively associated with altruism, whereas depression is negatively associated. However, the cross-sectional designs of these studies limit their epidemiological value. We examine the association of R/S and major depressive disorder (MDD) with altruism in a five year longitudinal study nested in a larger prospective study.Methods. Depressed and non-depressed individuals and their first- and second-generation offspring were assessed over several decades. At Year30 after baseline, R/S was measured using participants’ self-report; MDD, by clinical interview. At Year35, participants completed a measure of altruism. Adjusted odds ratios (AOR) were calculated using multivariate logistic regression; statistical significance, set at p<.05. two-tailed.Results. In the overall sample, both R/S and MDD were significantly associated with altruism, AOR 2.52 (95% CI 1.15-5.49) and AOR 2.43 (95% CI 1.05-5.64), respectively; in the High Risk group alone, the corresponding AORs were 4.69 (95% CI 1.39-15.84) and 4.74 (95% CI 1.92-11.72). Among highly R/S people in the High Risk group, the AOR for MDD with altruism was 22.55 (95% CI 1.23-414.60) p<.04; among the remainder, it was 3.12 (95% CI 0.63-15.30), a substantial but non-significant difference.Limitations. Altruism is based on self-report, not observation, hence, vulnerable to bias.Conclusions. MDD’s positive association with elevated altruism concurs with studies of posttraumatic growth in finding developmental growth from adversity. The conditions that foster MDD’s positive association with altruism and the contribution of R/S to this process requires further study.


2012 ◽  
Vol 43 (4) ◽  
pp. 673-687 ◽  
Author(s):  
S. Cohen-Woods ◽  
I. W. Craig ◽  
P. McGuffin

BackgroundIt has been well established that both genes and non-shared environment contribute substantially to the underlying aetiology of major depressive disorder (MDD). A comprehensive overview of genetic research in MDD is presented.MethodPapers were retrieved from PubMed up to December 2011, using many keywords including: depression, major depressive disorder, genetics, rare variants, gene–environment, whole genome, epigenetics, and specific candidate genes and variants. These were combined in a variety of permutations.ResultsLinkage studies have yielded some promising chromosomal regions in MDD. However, there is a continued lack of consistency in association studies, in both candidate gene and genome-wide association studies (GWAS). Numerous factors may account for variable results including the use of different diagnostic approaches, small samples in early studies, population stratification, epigenetic phenomena, copy number variation (CNV), rare variation, and phenotypic and allelic heterogeneity. The conflicting results are also probably, in part, a consequence of environmental factors not being considered or controlled for.ConclusionsEach research group has to identify what issues their sample may best address. We suggest that, where possible, more emphasis should be placed on the environment in molecular behavioural genetics to identify individuals at environmental high risk in addition to genetic high risk. Sequencing should be used to identify rare and alternative variation that may act as a risk factor, and a systems biology approach including gene–gene interactions and pathway analyses would be advantageous. GWAS may require even larger samples with reliably defined (sub)phenotypes.


NeuroImage ◽  
2011 ◽  
Vol 54 (2) ◽  
pp. 1607-1614 ◽  
Author(s):  
Gerd Wagner ◽  
Kathrin Koch ◽  
Claudia Schachtzabel ◽  
C. Christoph Schultz ◽  
Heinrich Sauer ◽  
...  

2020 ◽  
Author(s):  
Xingxing Li ◽  
Huifei Ge ◽  
Dongsheng Zhou ◽  
Xiangping Wu ◽  
Gangqiao Qi ◽  
...  

Abstract Background: VGF (nonacronymic) is a neuropeptide that plays an important role in the pathogenesis of major depressive disorder (MDD). However, no studies have yet investigated VGF levels in patients with MDD who are at risk of suicide. The purpose of the present study was to determine whether serum VGF levels are related to suicide risk in patients with MMD.Methods: A total of 107 patients with MDD and 40 normal control participated in the present study. The risk of suicide was assessed using the Nurses Global Assessment of Suicide Risk (NGASR). On this basis, 60 patients were assigned to a high-risk group (NGASR≥9) and 47 were assigned to a low-risk group (NGASR<9). The severity of depression was measured using the 17-item Hamilton Depression Rating Scale (HDRS). Levels of serum VGF were determined using a double antibody sandwich enzyme-linked immunosorbent assay.Results: Serum VGF levels in the high-risk group (883.34±139.67 pg/mL) were significantly lower than in the low-risk group (1020.56±131.76 pg/mL) and in the control group (1107.00±155.38 pg/mL) (F=31.90, p<0.001). In patients with MDD, suicide risk was significantly negatively correlated with VGF levels (r = -0.55, p=0.001). Conclusions: Reduced serum VGF levels are related to risk of suicide in patients with MDD, so VGF may be a biomarker of suicide risk in MDD.


Sign in / Sign up

Export Citation Format

Share Document